The Hematology Research Training Program at the University of Washington is designed to provide intensive post-doctoral research training in investigative hematology. Although the program emphasizes cell and molecular biology, and has well-established strengths in stem cells, hematopoiesis, cell and gene therapy, platelets and hemostasis, the pathogenesis of hematologic malignancies, and hematopoietic cell transplantation; clinical research and outcomes investigation are also supported and encouraged. Program faculty include established investigators with strong independent research programs from both basic science and clinical departments of the University of Washington. The faculty is based at the University of Washington campuses, the Fred Hutchinson Cancer Research Center, BloodWorks NW, Harborview Medical Center, the VA Puget Sound Health Care System, and Seattle Children's Hospital Research Institute. The goal of the training program is to develop the research, presentation, and grant-writing skills that trainees will need to establish independent research careers, and to train future leaders in research hematology. Trainees have MD, MD/PhD or PhD degrees. Many have completed clinical fellowship training in hematology, but others are basic researchers wishing to work in the field. Trainees are chosen through an application process and interviews with program faculty. They obtain research experience by working with a mentor, and gain skills in laboratory and/or clinical investigation, data analysis, publishing papers, presentation, and acquiring independent grant support. Bidirectional translational projects (bench to bedside and bedside to bench) are encouraged. Trainees typically receive two years of funding from the T32 program, but often continue their training longer under separate funding mechanisms, including K12, K23, K08 or K99R00 grants and foundation support. Training progress is monitored by the faculty mentor, a separate faculty advisor, the Program Directors, and the Division of Hematology faculty through regular research presentations, meetings with each trainee, and written evaluations. Each six months, trainees update their individual development plan (IDP) and formally present their research progress and career goals to a Research Oversight Committee (ROC) consisting of the trainee's mentors and the T32 PI. 100% and 83% of trainees who completed our program over the past 5 and 10 years, respectively, have academic medicine or industry research careers. Strengths of the program include: the diverse research opportunities, a qualified prominent senior faculty, the inclusion and mentorship of talented junior faculty, the structured mentorship of trainees, the inclusion of under-represented minority trainees, strong and varied didactic sessions, and a long track record spanning over five decades of training graduates that subsequently obtain academic (or industry) research positions and become independent, distinguished investigators and thought-leaders throughout hematology.

Public Health Relevance

There continues to be a need for rigorous scientists, and especially physician-scientists, in the field of hematology, since this discipline is at the forefront of translational investigation and modern medicine. This grant will support the training of hematology researchers at a critical time in their careers - the transition from post- doctoral fellow to independent investigator - and develop scientists that will advance hematology and health care in the USA.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
2T32HL007093-46
Application #
9853411
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Mondoro, Traci
Project Start
1975-07-01
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
46
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Baker, Kathryn T; Salk, Jesse J; Brentnall, Teresa A et al. (2018) Precancer in ulcerative colitis: the role of the field effect and its clinical implications. Carcinogenesis 39:11-20
Klein, Jason C; Keith, Aidan; Agarwal, Vikram et al. (2018) Functional characterization of enhancer evolution in the primate lineage. Genome Biol 19:99
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :
Hart, Matthew R; Anderson, Donovan J; Porter, Christopher C et al. (2018) Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations. PLoS Genet 14:e1007642
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Samuelson Bannow, B T; Konkle, B A (2018) Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review. Thromb Res 163:138-145
Wang, Tzu-Fei; Li, Ang; Garcia, David (2018) Managing thrombosis in cancer patients. Res Pract Thromb Haemost 2:429-438
Appelbaum, Jacob; Wells, David; Hiatt, Joseph B et al. (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6:82
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243
Li, A; Khalighi, P R; Wu, Q et al. (2018) External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost 16:164-169

Showing the most recent 10 out of 105 publications